Targeted Therapeutics in Breast Cancer: Promise, Progress, and the Challenge of Triple-negative Subtype.
Advances in targeted and immune-based therapies are transforming breast cancer care and Leveraging molecular insights, particularly for TNBC, is crucial to delivering personalised, clinically meaningful treatments and improving outcomes across all subtypes.